financetom
Business
financetom
/
Business
/
India's 3M reports quarterly profit rise on strong demand in healthcare, consumer segments
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
India's 3M reports quarterly profit rise on strong demand in healthcare, consumer segments
Aug 7, 2025 1:55 AM

Aug 7 (Reuters) - Diversified products maker 3M India

reported a year-on-year rise in profit after three

consecutive quarters of decline, buoyed by strong demand in its

healthcare and consumer segments.

The company, which makes everything from 'Post-it' notes to

medical gear, reported a 13.1% rise in profit after tax to 1.78

billion rupees ($20.30 million) for the first quarter ended June

30, from 1.57 billion rupees a year ago.

The Indian arm of U.S. conglomerate 3M ( MMM ) has logged

robust demand in sectors such as healthcare, infrastructure and

electronics as India's own manufacturing activities scale up,

led by higher government expenditure and strong economic growth.

3M India's revenue rose 14.3% to 11.96 billion rupees,

marking its highest growth in three quarters. Expenses rose

roughly 13%.

Last month parent 3M ( MMM ) raised its full-year profit

forecast and projected a smaller hit from U.S. tariffs to its

2025 earnings.

Sales in both its healthcare and consumer segments, which

account for 20% and 11% of the top line, respective, rose 20%

each.

Its biggest segment, transportation and electronics, which

makes up about 37% of the overall revenue, saw an 11% rise in

sales.

Shares of 3M India were down 2.22% in a weak broader market

after the U.S. doubled the tariffs on imported Indian goods to

50%, stoking concerns over the economic impact of heightened

trade tensions.

($1 = 87.6900 Indian rupees)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
BioCryst Pharmaceuticals Receives Approval for Orladeyo in Colombia
BioCryst Pharmaceuticals Receives Approval for Orladeyo in Colombia
Jun 13, 2025
07:25 AM EDT, 06/13/2025 (MT Newswires) -- BioCryst Pharmaceuticals ( BCRX ) said Friday that Colombia's National Institute of Drug and Food Surveillance has approved Orladeyo to prevent hereditary angioedema attacks in patients at least 12 years old. The company said it has an exclusive collaboration with Pint Pharma for Orladeyo in the pan-Latin America region, with Pint in charge...
Westwater Resources to Sell Convertible Notes in Public Offering
Westwater Resources to Sell Convertible Notes in Public Offering
Jun 13, 2025
07:28 AM EDT, 06/13/2025 (MT Newswires) -- Westwater Resources ( WWR ) said Friday it has agreed to sell convertible notes for up to $5 million to certain institutional investors in a registered public offering. The notes will be convertible into the company's common shares, according to a regulatory filing. ...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Roots Q1 Net Loss Narrows, But Misses Forecast; Revenue Rises
Roots Q1 Net Loss Narrows, But Misses Forecast; Revenue Rises
Jun 13, 2025
07:30 AM EDT, 06/13/2025 (MT Newswires) -- Roots (ROOT.TO) on Friday said its first-quarter net loss narrowed, coming in slightly below forecasts, as revenue increased. The clothing retailer said the net loss shrunk to $7.9 million, or $0.20 per share, from $8.9 million, or $0.22 per share, in the prior year period. The result was slightly below the consensus analyst...
Copyright 2023-2026 - www.financetom.com All Rights Reserved